<DOC>
	<DOCNO>NCT00794807</DOCNO>
	<brief_summary>Previous Biogen study provide experience tolerability , immunogenicity , efficacy single multiple 12-week course therapy alefacept . At stage , experience large study , well FDA-approved labeling , confine treatment course 12 week . The purpose present study offer extend course therapy alefacept .</brief_summary>
	<brief_title>Safety Tolerability Repeat Courses IM Alefacept</brief_title>
	<detailed_description>Twenty statistically match patient ( 15 male , 5 female , age 28 70 year , median 50 year ) moderate severe psoriasis ( PASI : 7-36 ) include study . They treat 15 mg alefacept i.m . weekly . Peripheral blood take prior first alefacept application weekly week five thereafter every second week , end treatment week 13 . At time point severity disease thereby possible reduction symptom evaluate apply PASI . Investigators analyse sample blind outcome study . The protocol concern human subject approve ethic commission Charit√© University Medicine Berlin Campus Mitte , Germany .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Immunoglobulin G</mesh_term>
	<mesh_term>Alefacept</mesh_term>
	<criteria>1 . Must give write informed consent . 2 . Must require systemic therapy phototherapy psoriasis , determine investigator prior Visit 1 . 1 . Female subject postmenopausal least 1 year , surgically sterile , willing practice effective contraception study . Nursing mother , pregnant woman woman plan become pregnant study exclude . 2 . Current enrollment investigational study subject receive type drug , biologic , nondrug therapy ( participation registrytype study allow ) . 3 . Serious local infection ( e.g. , abscess ) systemic infection ( e.g. , pneumonia , septicemia ) within 3 month prior first dose investigational drug . 4 . Any subject whose CD4+ lymphocyte count study entry le 404 cells/mm3 . 5 . Treatment another investigational drug approve therapy investigational use within 28 day prior investigational drug administration . 6 . Treatment systemic retinoids , systemic steroid , methotrexate , cyclosporine , azathioprine , thioguanine systemic immunosuppressant agent within 28 day prior investigational drug administration . 7 . Phototherapy , include Ultraviolet B ( UVB ) Psoralen + Ultraviolet A ( PUVA ) , within 28 day prior investigational drug administration . 8 . Known HIV+ , know viral Hepatitis infection , know tuberculosis infection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2008</verification_date>
	<keyword>Alefacept</keyword>
	<keyword>Skin Diseases</keyword>
	<keyword>Psoriasis</keyword>
	<keyword>Skin Diseases , Papulosquamos</keyword>
	<keyword>Therapeutic Uses</keyword>
	<keyword>Dermatologic Agents</keyword>
</DOC>